Cell treatment on track for Phase II stroke trial

04/27/2012 | ProactiveInvestors.co.uk (U.K.)

The stem cell therapy ReN001 is being used in early clinical trials to treat 12 patients disabled by stroke, and an application is on track for a midstage study in 2013. The therapy is based on stem cell developer ReNeuron's lead neural stem cell line. ReNeuron is also developing treatments for peripheral arterial disease and retina diseases.

View Full Article in:

ProactiveInvestors.co.uk (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI